Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.

The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to a question mark over the integrity of clinical data used to support its ...

Sobi has received a CRL from the US FDA regarding its BLA for NASP, an investigational therapy intended for adults with uncontrolled gout.

Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.

Antares will lead all research and apply its drug discovery engine to a “limited” number of undisclosed oncology targets until Novartis decides to license the asset in questio ...

Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.

AbbVie's multi-billion-dollar Apogee bid could further cement the former's leading position in the immunology space as competition heats up.

Immunai and Boehringer Ingelheim have entered into a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases.

Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to full health”. In its midyear outlook report, the firm stated that ...

Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug, with that forecast having just become ...

RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.

Former FDA employees discussed whether the agency’s commitment to openness risks creating a lack of clarity on official policies.